60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
60 Degrees Pharmaceuticals's gross profit for the twelve months ending Jun 30, 2026 was $215.79K, down 25.2% year over year. For fiscal 2025 it was $223.78K, up 0.4% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $223.78K | +0.4% |
| FY2024 | Dec 31, 2024 | $222.81K | – |
| FY2023 | Dec 31, 2023 | -$220.98K | – |
| FY2022 | Dec 31, 2022 | -$209.16K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.80K | +11.6% |
| Q1 FY2026 | Mar 31, 2026 | $76.38K | -15.4% |
| Q4 FY2025 | Dec 31, 2025 | $182.70K | +47.9% |
| Q3 FY2025 | Sep 30, 2025 | -$100.09K | -524.0% |
| Q2 FY2025 | Jun 30, 2025 | $50.88K | +43.7% |
| Q1 FY2025 | Mar 31, 2025 | $90.28K | +124.4% |
| Q4 FY2024 | Dec 31, 2024 | $123.56K | – |
| Q3 FY2024 | Sep 30, 2024 | $23.61K | – |
| Q2 FY2024 | Jun 30, 2024 | $35.41K | – |
| Q1 FY2024 | Mar 31, 2024 | $40.24K | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.58K | -127.1% |
| Q3 FY2023 | Sep 30, 2023 | -$20.01K | – |
| Q2 FY2023 | Jun 30, 2023 | -$124.45K | – |
| Q1 FY2023 | Mar 31, 2023 | -$55.95K | – |
| Q3 FY2022 | Sep 30, 2022 | $75.90K | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.95K | – |